Jnk3 modulators and methods of use
CA 2302874 C · Owner: Kuan, Chia-Yi · Inventors: Yang, Di; Flavell, Richard A.; Whitmarsh, Alan J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The c-Jun NH2-terminal kinase (JNK) group of MAP kinases are activated by exposure of cells to environmental stress. The role of JNK in the brain was examined by targeted disruption of the gene that encodes the neuronal isoform JNK3. It was found that JNK3 is required for the normal response to seizure activity. Methods of screening for molecules and compounds that decrease JNK3 expression or activity are described. Such molecules or compounds are useful for treating disorders involving excitotoxicity such as seizure disorders Alzheimer's disease, Huntington disease Parkinson's disease, and ischaemia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 5, 1998 and granted July 12, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 5, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 5, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.